From FierceBioTech.com…
Looking to be the dominant player in COVID-19, Pfizer is kick-starting a phase 2/3 clinical trial for an oral therapeutic antiviral for adults who have been exposed to the coronavirus.
If successful, the therapy will join Pfizer’s BioNTech-partnered mega blockbuster COVID-19 vaccine in a portfolio of products that could help stem the pandemic.
PF-07321332, a name that really rolls off the tongue, will be examined in a phase 2/3 trial called EPIC-PEP in combination with common HIV antiviral ritonavir to prevent COVID-19 in adults who are living in the same home as someone who has the respiratory disease.
The main goal is to assess the safety and efficacy of the treatment in preventing COVID-19 infection over 14 days. Pfizer is hoping the therapy can eventually be prescribed at the first sign of infection or the first indication of exposure.
